Skip to main content

Peer Review reports

From: High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine

Original Submission
7 Aug 2021 Submitted Original manuscript
25 Aug 2021 Author responded Author comments - Qingyuan Zhang
1 Sep 2021 Author responded Author comments - Qingyuan Zhang
Resubmission - Version 2
25 Aug 2021 Submitted Manuscript version 2
19 Sep 2021 Reviewed Reviewer Report
5 Oct 2021 Author responded Author comments - Qingyuan Zhang
Resubmission - Version 3
5 Oct 2021 Submitted Manuscript version 3
8 Oct 2021 Author responded Author comments - Qingyuan Zhang
Resubmission - Version 4
8 Oct 2021 Submitted Manuscript version 4
14 Oct 2021 Author responded Author comments - Qingyuan Zhang
Resubmission - Version 5
14 Oct 2021 Submitted Manuscript version 5
14 Nov 2021 Reviewed Reviewer Report
17 Nov 2021 Reviewed Reviewer Report - Chieh-Han Chuang
24 Nov 2021 Reviewed Reviewer Report
29 Nov 2021 Author responded Author comments - Qingyuan Zhang
Resubmission - Version 6
29 Nov 2021 Submitted Manuscript version 6
6 Dec 2021 Author responded Author comments - Qingyuan Zhang
Resubmission - Version 7
6 Dec 2021 Submitted Manuscript version 7
14 Dec 2021 Reviewed Reviewer Report
17 Dec 2021 Reviewed Reviewer Report - Chieh-Han Chuang
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
20 Dec 2021 Editorially accepted
3 Jan 2022 Article published 10.1186/s12885-021-09131-6

You can find further information about peer review here.

Back to article page